Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis

Table 2 Kaplan-Meier estimates for incidence of cirrhosis at select timepoints

Time post-index	CFTR modulator + ursodiol	CFTR Modulator only	Ursodiol only	Neither therapy
3 mo	0.01	0	0.019	0.0002
6 mo	0.01	0	0.032	0.001
1 yr	0.01	0	0.059	0.001
2 yr	0.01	0	0.075	0.004
3 yr	0.01	0	0.091	0.005
4 yr	0.01	0	0.101	0.007

CFTR modulators: Cystic fibrosis transmembrane regulator modulators.